Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Drug (Brand / Generic)

Baxdela™ / delafloxacin

Companies / Licensee

Melinta Therapeutics and Ligand Pharmaceuticals / Menarini Group

Therapy Class

Fluoroquinolone antibiotic

Current Indication

Acute bacterial skin and skin structure infections (ABSSSI)

Market Sector

Anti-infectives

Development Status

Approved in the US
Expand

Go Top